---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-108171"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:29:45.619183+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives

## Summary
- Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.
- Board commenced evaluation of strategic alternatives on July 22, 2024; Oppenheimer & Co. retained as exclusive financial adviser.
- Reduction-in-force commenced August 1, 2024, continuing in stages; clinical development of voruciclib discontinued.
- Options include out-licensing programs and M&A; company will not disclose developments unless completed or required.

## SEC filing metadata
- accession: 0000950170-24-108171
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/0000950170-24-108171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/meip-20240919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-108171
- JSON: https://secwatch.observer/filing/0000950170-24-108171.json
- Plain text: https://secwatch.observer/filing/0000950170-24-108171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.